Surgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II–III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study
Authors:
- Hiroki SakaiHSHiroki Sakai
- Takayuki HatakeyamaTHTakayuki Hatakeyama
- Takahiro HommaTHTakahiro Homma
- Kanji OtsuboKOKanji Otsubo
- Norifumi KakizakiNKNorifumi Kakizaki
- Hideki MarushimaHMHideki Marushima
- Koji KojimaKKKoji Kojima
- Kei MorikawaKMKei Morikawa
- Naoki FuruyaNFNaoki Furuya
- Masamichi MineshitaMMMasamichi Mineshita
- Yoshiya SugiuraYSYoshiya Sugiura
- Junki KoikeJKJunki Koike
Open Access
Abstract
Background: Neoadjuvant chemoimmunotherapy has emerged as a standard option for resectable stage II–III non-small cell lung cancer (NSCLC); however, its impact on surgical feasibility, operative complexity, and perioperative outcomes remains incompletely characterized. We compared surgical feasibility, complexity, and perioperative outcomes across different neoadjuvant strategies. Methods: This single-center retrospective study included patients with stage II–III NSCLC who underwent curative-intent resection following neoadjuvant chemoimmunotherapy (neo-CIT), chemotherapy alone (neo-CT), or chemoradiotherapy (neo-CRT) during the same period. Surgical complexity was assessed using a four-level empirical grading scale. Perioperative outcomes, pathological response, and complications were compared among treatment groups using appropriate nonparametric statistical methods. Results: Twenty-four patients were included in the analysis (neo-CIT, n = 8; neo-CT, n = 12; neo-CRT, n = 4). R0 resection was achieved in 100%, 66.7%, and 75% of patients in the neo-CIT, neo-CT, and neo-CRT groups, respectively. Operative time, estimated blood loss, length of hospital stay, and overall postoperative complication rates did not differ significantly among groups. Thirty-day mortality was 0% in all groups, and 90-day mortality was 12.5% in the neo-CIT group and 0% in the neo-CT and neo-CRT groups. Surgical complexity scores were high across all cohorts and, when analyzed across the entire cohort, were not significantly associated with longer operative time (p = 0.16), greater blood loss (p = 0.83), or pathological response (p = 0.55). Neo-CIT was not associated with increased objective perioperative risk compared with neoadjuvant chemotherapy or chemoradiotherapy. Conclusions: In this single-institution exploratory analysis, neoadjuvant chemoimmunotherapy appeared to be surgically feasible and did not result in an apparent increase in perioperative risk compared with other neoadjuvant strategies. Although surgeons perceived increased operative complexity, objective perioperative risk remained acceptable when procedures were performed by experienced thoracic surgeons. However, given the limited sample size and lack of statistical power, these findings should be interpreted with caution and should not be considered evidence of equivalence.Keywords
All Related Versions
Funding Information
- Japan Agency for Medical Research and Development (JP25ck0106050)
This publication has 31 references indexed in Scilit:
- A Multifactorial Model to Predict the Surgical Complexity of Lung Resection After Neoadjuvant ChemoimmunotherapyAnnals of Thoracic Surgery Short Reports, 2025
- Immunotherapy for resectable lung cancerCancer, 2025
- Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trialThe Lancet Respiratory Medicine, 2024
- Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2024
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2024
- Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2023
- Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2022
- IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant TherapyJournal of Thoracic Oncology, 2020
- Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2019
- Mechanisms of disseminated cancer cell dormancy: an awakening fieldNature Reviews Cancer, 2014